Translational Drug Development (TD2)
Kori Capitummino is a seasoned professional in clinical data management with a robust background that includes current experience as a Clinical Data Associate at Translational Drug Development (TD2) since April 2021. Prior roles encompass positions such as Lead Data Coordinator and Data Manager at ERT from May 2018 to April 2021, and Associate Data Manager and Data Support Specialist at iCardiac from November 2016 to May 2018. Kori took a career hiatus to focus on family from January 2013 to November 2016 and previously worked as a Customer Service Manager at Amsale Aberra, L.L.C., and Compliance Manager at Hirtle, Callaghan & Co. Kori holds a Bachelor's degree in Economics from SUNY Geneseo, obtained in 2000.
This person is not in any offices
Translational Drug Development (TD2)
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.